Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc. CATB Peers
See (CATB) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CATB | $8.54 | -6.97% | 234.9M | N/A | N/A | N/A |
| VRTX | $455.45 | -1.00% | 117B | -118.61 | -$3.84 | N/A |
| REGN | $529.24 | +1.42% | 56.2B | 13.45 | $39.36 | +0.33% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $307.87 | +1.05% | 40.1B | -146.60 | -$2.10 | N/A |
| ARGX | $577.62 | -1.56% | 35.3B | 35.22 | $16.40 | N/A |
| BNTX | $106.74 | +1.73% | 25.7B | -29.32 | -$3.64 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $34.84 | -1.22% | 19.6B | 14.16 | $2.46 | +2.46% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
CATB vs VRTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, VRTX has a market cap of 117B. Regarding current trading prices, CATB is priced at $8.54, while VRTX trades at $455.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -118.61. In terms of profitability, CATB's ROE is N/A, compared to VRTX's ROE of -0.06%. Regarding short-term risk, CATB is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs REGN Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, REGN has a market cap of 56.2B. Regarding current trading prices, CATB is priced at $8.54, while REGN trades at $529.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 13.45. In terms of profitability, CATB's ROE is N/A, compared to REGN's ROE of +0.15%. Regarding short-term risk, CATB is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs SGEN Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CATB is priced at $8.54, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CATB's ROE is N/A, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CATB is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ALNY Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ALNY has a market cap of 40.1B. Regarding current trading prices, CATB is priced at $8.54, while ALNY trades at $307.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is -146.60. In terms of profitability, CATB's ROE is N/A, compared to ALNY's ROE of -5.09%. Regarding short-term risk, CATB is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ARGX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ARGX has a market cap of 35.3B. Regarding current trading prices, CATB is priced at $8.54, while ARGX trades at $577.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 35.22. In terms of profitability, CATB's ROE is N/A, compared to ARGX's ROE of +0.23%. Regarding short-term risk, CATB is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs BNTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, BNTX has a market cap of 25.7B. Regarding current trading prices, CATB is priced at $8.54, while BNTX trades at $106.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -29.32. In terms of profitability, CATB's ROE is N/A, compared to BNTX's ROE of -0.04%. Regarding short-term risk, CATB is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs BGNE Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CATB is priced at $8.54, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CATB's ROE is N/A, compared to BGNE's ROE of -0.12%. Regarding short-term risk, CATB is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RPRX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RPRX has a market cap of 19.6B. Regarding current trading prices, CATB is priced at $8.54, while RPRX trades at $34.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 14.16. In terms of profitability, CATB's ROE is N/A, compared to RPRX's ROE of +0.16%. Regarding short-term risk, CATB is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs DNA-WT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CATB is priced at $8.54, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CATB's ROE is N/A, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, CATB is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs SMMT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, SMMT has a market cap of 14.6B. Regarding current trading prices, CATB is priced at $8.54, while SMMT trades at $19.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -58.18. In terms of profitability, CATB's ROE is N/A, compared to SMMT's ROE of -0.70%. Regarding short-term risk, CATB is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs GMAB Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, GMAB has a market cap of 14.1B. Regarding current trading prices, CATB is priced at $8.54, while GMAB trades at $22.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 13.42. In terms of profitability, CATB's ROE is N/A, compared to GMAB's ROE of +0.26%. Regarding short-term risk, CATB is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs INCY Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, INCY has a market cap of 13.1B. Regarding current trading prices, CATB is priced at $8.54, while INCY trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 338.75. In terms of profitability, CATB's ROE is N/A, compared to INCY's ROE of +0.01%. Regarding short-term risk, CATB is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs UTHR Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, UTHR has a market cap of 12.8B. Regarding current trading prices, CATB is priced at $8.54, while UTHR trades at $283.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 11.29. In terms of profitability, CATB's ROE is N/A, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CATB is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs KRTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CATB is priced at $8.54, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CATB's ROE is N/A, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CATB is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs EXEL Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, EXEL has a market cap of 11.3B. Regarding current trading prices, CATB is priced at $8.54, while EXEL trades at $41.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 18.99. In terms of profitability, CATB's ROE is N/A, compared to EXEL's ROE of +0.29%. Regarding short-term risk, CATB is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs BMRN Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, CATB is priced at $8.54, while BMRN trades at $56.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 20.82. In terms of profitability, CATB's ROE is N/A, compared to BMRN's ROE of +0.09%. Regarding short-term risk, CATB is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MRNA Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MRNA has a market cap of 10.3B. Regarding current trading prices, CATB is priced at $8.54, while MRNA trades at $26.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -3.05. In terms of profitability, CATB's ROE is N/A, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CATB is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ASND Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ASND has a market cap of 10.3B. Regarding current trading prices, CATB is priced at $8.54, while ASND trades at $170.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -25.73. In terms of profitability, CATB's ROE is N/A, compared to ASND's ROE of +1.91%. Regarding short-term risk, CATB is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RXDX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CATB is priced at $8.54, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CATB's ROE is N/A, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CATB is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs IMGN Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CATB is priced at $8.54, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CATB's ROE is N/A, compared to IMGN's ROE of -1.43%. Regarding short-term risk, CATB is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs BPMC Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, CATB is priced at $8.54, while BPMC trades at $127.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -50.98. In terms of profitability, CATB's ROE is N/A, compared to BPMC's ROE of -0.49%. Regarding short-term risk, CATB is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CERE Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CATB is priced at $8.54, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, CATB's ROE is N/A, compared to CERE's ROE of -0.43%. Regarding short-term risk, CATB is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs TECH Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, TECH has a market cap of 7.9B. Regarding current trading prices, CATB is priced at $8.54, while TECH trades at $50.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 60.87. In terms of profitability, CATB's ROE is N/A, compared to TECH's ROE of +0.06%. Regarding short-term risk, CATB is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs VRNA Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, VRNA has a market cap of 7.8B. Regarding current trading prices, CATB is priced at $8.54, while VRNA trades at $92.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -46.10. In terms of profitability, CATB's ROE is N/A, compared to VRNA's ROE of -0.90%. Regarding short-term risk, CATB is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ROIVW Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, CATB is priced at $8.54, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, CATB's ROE is N/A, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, CATB is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for CATB.
CATB vs ROIV Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, CATB is priced at $8.54, while ROIV trades at $11.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -15.30. In terms of profitability, CATB's ROE is N/A, compared to ROIV's ROE of -0.02%. Regarding short-term risk, CATB is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RVMD Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RVMD has a market cap of 7.6B. Regarding current trading prices, CATB is priced at $8.54, while RVMD trades at $40.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -9.78. In terms of profitability, CATB's ROE is N/A, compared to RVMD's ROE of -0.37%. Regarding short-term risk, CATB is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs BBIO Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, BBIO has a market cap of 7.6B. Regarding current trading prices, CATB is priced at $8.54, while BBIO trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -11.17. In terms of profitability, CATB's ROE is N/A, compared to BBIO's ROE of +0.49%. Regarding short-term risk, CATB is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CORT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, CATB is priced at $8.54, while CORT trades at $70.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 60.97. In terms of profitability, CATB's ROE is N/A, compared to CORT's ROE of +0.20%. Regarding short-term risk, CATB is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs JAZZ Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, CATB is priced at $8.54, while JAZZ trades at $108.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 14.74. In terms of profitability, CATB's ROE is N/A, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, CATB is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs HALO Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, HALO has a market cap of 6.7B. Regarding current trading prices, CATB is priced at $8.54, while HALO trades at $53.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 14.36. In terms of profitability, CATB's ROE is N/A, compared to HALO's ROE of +1.22%. Regarding short-term risk, CATB is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RETA Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CATB is priced at $8.54, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, CATB's ROE is N/A, compared to RETA's ROE of +0.47%. Regarding short-term risk, CATB is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MDGL Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MDGL has a market cap of 6.6B. Regarding current trading prices, CATB is priced at $8.54, while MDGL trades at $295.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -16.56. In terms of profitability, CATB's ROE is N/A, compared to MDGL's ROE of -0.51%. Regarding short-term risk, CATB is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs TGTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, CATB is priced at $8.54, while TGTX trades at $36.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 144.04. In terms of profitability, CATB's ROE is N/A, compared to TGTX's ROE of +0.19%. Regarding short-term risk, CATB is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs IONS Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, IONS has a market cap of 5.7B. Regarding current trading prices, CATB is priced at $8.54, while IONS trades at $35.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -11.90. In terms of profitability, CATB's ROE is N/A, compared to IONS's ROE of -0.92%. Regarding short-term risk, CATB is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs NUVL Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, CATB is priced at $8.54, while NUVL trades at $78.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -16.94. In terms of profitability, CATB's ROE is N/A, compared to NUVL's ROE of -0.31%. Regarding short-term risk, CATB is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ABCM Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CATB is priced at $8.54, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CATB's ROE is N/A, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CATB is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ISEE Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CATB is priced at $8.54, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CATB's ROE is N/A, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CATB is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs AMRN Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, AMRN has a market cap of 5.4B. Regarding current trading prices, CATB is priced at $8.54, while AMRN trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas AMRN's P/E ratio is -2.99. In terms of profitability, CATB's ROE is N/A, compared to AMRN's ROE of -0.17%. Regarding short-term risk, CATB is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs TLX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, CATB is priced at $8.54, while TLX trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 178.78. In terms of profitability, CATB's ROE is N/A, compared to TLX's ROE of +0.14%. Regarding short-term risk, CATB is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs AXSM Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, CATB is priced at $8.54, while AXSM trades at $104.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -18.04. In terms of profitability, CATB's ROE is N/A, compared to AXSM's ROE of -3.64%. Regarding short-term risk, CATB is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ADMA Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ADMA has a market cap of 5B. Regarding current trading prices, CATB is priced at $8.54, while ADMA trades at $20.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ADMA's P/E ratio is 24.76. In terms of profitability, CATB's ROE is N/A, compared to ADMA's ROE of +0.72%. Regarding short-term risk, CATB is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ALKS Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ALKS has a market cap of 4.9B. Regarding current trading prices, CATB is priced at $8.54, while ALKS trades at $29.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 14.20. In terms of profitability, CATB's ROE is N/A, compared to ALKS's ROE of +0.25%. Regarding short-term risk, CATB is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ZLAB Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ZLAB has a market cap of 4.5B. Regarding current trading prices, CATB is priced at $8.54, while ZLAB trades at $41.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ZLAB's P/E ratio is -16.40. In terms of profitability, CATB's ROE is N/A, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, CATB is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs PCVX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, PCVX has a market cap of 4.5B. Regarding current trading prices, CATB is priced at $8.54, while PCVX trades at $34.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -8.66. In terms of profitability, CATB's ROE is N/A, compared to PCVX's ROE of -0.17%. Regarding short-term risk, CATB is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ALPN Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CATB is priced at $8.54, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CATB's ROE is N/A, compared to ALPN's ROE of -0.04%. Regarding short-term risk, CATB is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs AKRO Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, AKRO has a market cap of 4.4B. Regarding current trading prices, CATB is priced at $8.54, while AKRO trades at $55.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.83. In terms of profitability, CATB's ROE is N/A, compared to AKRO's ROE of -0.32%. Regarding short-term risk, CATB is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs OPT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CATB is priced at $8.54, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, CATB's ROE is N/A, compared to OPT's ROE of +2.60%. Regarding short-term risk, CATB is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MRTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CATB is priced at $8.54, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CATB's ROE is N/A, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CATB is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CYTK Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CYTK has a market cap of 4.1B. Regarding current trading prices, CATB is priced at $8.54, while CYTK trades at $34.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -6.50. In terms of profitability, CATB's ROE is N/A, compared to CYTK's ROE of +8.01%. Regarding short-term risk, CATB is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MRUS Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MRUS has a market cap of 4.1B. Regarding current trading prices, CATB is priced at $8.54, while MRUS trades at $54.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -13.13. In terms of profitability, CATB's ROE is N/A, compared to MRUS's ROE of -0.41%. Regarding short-term risk, CATB is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs PTCT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, CATB is priced at $8.54, while PTCT trades at $51.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.87. In terms of profitability, CATB's ROE is N/A, compared to PTCT's ROE of -0.72%. Regarding short-term risk, CATB is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RYTM Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, CATB is priced at $8.54, while RYTM trades at $62.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -22.45. In terms of profitability, CATB's ROE is N/A, compared to RYTM's ROE of -1.80%. Regarding short-term risk, CATB is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs SLNO Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, SLNO has a market cap of 4B. Regarding current trading prices, CATB is priced at $8.54, while SLNO trades at $79.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas SLNO's P/E ratio is -16.70. In terms of profitability, CATB's ROE is N/A, compared to SLNO's ROE of -0.78%. Regarding short-term risk, CATB is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs KRYS Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, CATB is priced at $8.54, while KRYS trades at $137.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 32.95. In terms of profitability, CATB's ROE is N/A, compared to KRYS's ROE of +0.14%. Regarding short-term risk, CATB is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RNA Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RNA has a market cap of 3.8B. Regarding current trading prices, CATB is priced at $8.54, while RNA trades at $31.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RNA's P/E ratio is -10.46. In terms of profitability, CATB's ROE is N/A, compared to RNA's ROE of -0.27%. Regarding short-term risk, CATB is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RYZB Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CATB is priced at $8.54, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CATB's ROE is N/A, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CATB is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CBAY Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CATB is priced at $8.54, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CATB's ROE is N/A, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CATB is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ACLX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ACLX has a market cap of 3.6B. Regarding current trading prices, CATB is priced at $8.54, while ACLX trades at $66.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -22.09. In terms of profitability, CATB's ROE is N/A, compared to ACLX's ROE of -0.35%. Regarding short-term risk, CATB is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs ACAD Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, CATB is priced at $8.54, while ACAD trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 15.85. In terms of profitability, CATB's ROE is N/A, compared to ACAD's ROE of +0.35%. Regarding short-term risk, CATB is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CRSP Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CRSP has a market cap of 3.6B. Regarding current trading prices, CATB is priced at $8.54, while CRSP trades at $41.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -9.21. In terms of profitability, CATB's ROE is N/A, compared to CRSP's ROE of -0.20%. Regarding short-term risk, CATB is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs SRPT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, SRPT has a market cap of 3.6B. Regarding current trading prices, CATB is priced at $8.54, while SRPT trades at $36.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas SRPT's P/E ratio is -13.70. In terms of profitability, CATB's ROE is N/A, compared to SRPT's ROE of -0.20%. Regarding short-term risk, CATB is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs RARE Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, CATB is priced at $8.54, while RARE trades at $37.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas RARE's P/E ratio is -6.43. In terms of profitability, CATB's ROE is N/A, compared to RARE's ROE of -1.86%. Regarding short-term risk, CATB is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs SWTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CATB is priced at $8.54, while SWTX trades at $46.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.72. In terms of profitability, CATB's ROE is N/A, compared to SWTX's ROE of -0.51%. Regarding short-term risk, CATB is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs PTGX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, CATB is priced at $8.54, while PTGX trades at $56.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 72.27. In terms of profitability, CATB's ROE is N/A, compared to PTGX's ROE of +0.09%. Regarding short-term risk, CATB is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs LEGN Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, CATB is priced at $8.54, while LEGN trades at $36.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -31.21. In terms of profitability, CATB's ROE is N/A, compared to LEGN's ROE of -0.20%. Regarding short-term risk, CATB is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MTSR Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MTSR has a market cap of 3.1B. Regarding current trading prices, CATB is priced at $8.54, while MTSR trades at $29.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -11.61. In terms of profitability, CATB's ROE is N/A, compared to MTSR's ROE of -0.63%. Regarding short-term risk, CATB is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for CATB.
CATB vs SRRK Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, SRRK has a market cap of 3.1B. Regarding current trading prices, CATB is priced at $8.54, while SRRK trades at $32.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -12.73. In terms of profitability, CATB's ROE is N/A, compared to SRRK's ROE of -1.18%. Regarding short-term risk, CATB is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs KYMR Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, CATB is priced at $8.54, while KYMR trades at $46.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -15.10. In terms of profitability, CATB's ROE is N/A, compared to KYMR's ROE of -0.30%. Regarding short-term risk, CATB is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CRNX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CRNX has a market cap of 3B. Regarding current trading prices, CATB is priced at $8.54, while CRNX trades at $31.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -8.37. In terms of profitability, CATB's ROE is N/A, compared to CRNX's ROE of -0.31%. Regarding short-term risk, CATB is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs VKTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, CATB is priced at $8.54, while VKTX trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -22.48. In terms of profitability, CATB's ROE is N/A, compared to VKTX's ROE of -0.14%. Regarding short-term risk, CATB is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for CATB.
CATB vs CPRX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CPRX has a market cap of 2.9B. Regarding current trading prices, CATB is priced at $8.54, while CPRX trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 14.99. In terms of profitability, CATB's ROE is N/A, compared to CPRX's ROE of +0.28%. Regarding short-term risk, CATB is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MORF Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CATB is priced at $8.54, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, CATB's ROE is N/A, compared to MORF's ROE of -0.22%. Regarding short-term risk, CATB is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MOR Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CATB is priced at $8.54, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, CATB's ROE is N/A, compared to MOR's ROE of +2.51%. Regarding short-term risk, CATB is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MLTX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MLTX has a market cap of 2.8B. Regarding current trading prices, CATB is priced at $8.54, while MLTX trades at $44.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MLTX's P/E ratio is -19.20. In terms of profitability, CATB's ROE is N/A, compared to MLTX's ROE of -0.00%. Regarding short-term risk, CATB is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs AAPG Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, AAPG has a market cap of 2.7B. Regarding current trading prices, CATB is priced at $8.54, while AAPG trades at $31.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas AAPG's P/E ratio is -42.66. In terms of profitability, CATB's ROE is N/A, compared to AAPG's ROE of -2.50%. Regarding short-term risk, CATB is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs KDNY Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, CATB is priced at $8.54, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas KDNY's P/E ratio is -12.47. In terms of profitability, CATB's ROE is N/A, compared to KDNY's ROE of -0.41%. Regarding short-term risk, CATB is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs IBRX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, IBRX has a market cap of 2.7B. Regarding current trading prices, CATB is priced at $8.54, while IBRX trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -5.38. In terms of profitability, CATB's ROE is N/A, compared to IBRX's ROE of +0.65%. Regarding short-term risk, CATB is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs IMVT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, CATB is priced at $8.54, while IMVT trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -5.74. In terms of profitability, CATB's ROE is N/A, compared to IMVT's ROE of -0.81%. Regarding short-term risk, CATB is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs APGE Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, APGE has a market cap of 2.6B. Regarding current trading prices, CATB is priced at $8.54, while APGE trades at $44.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -12.31. In terms of profitability, CATB's ROE is N/A, compared to APGE's ROE of -0.19%. Regarding short-term risk, CATB is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for CATB.
CATB vs MYOV Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, CATB is priced at $8.54, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MYOV's P/E ratio is -14.05. In terms of profitability, CATB's ROE is N/A, compared to MYOV's ROE of +0.50%. Regarding short-term risk, CATB is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs XENE Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, CATB is priced at $8.54, while XENE trades at $32.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -10.17. In terms of profitability, CATB's ROE is N/A, compared to XENE's ROE of -0.32%. Regarding short-term risk, CATB is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs MIRM Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, CATB is priced at $8.54, while MIRM trades at $49.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -30.83. In terms of profitability, CATB's ROE is N/A, compared to MIRM's ROE of -0.34%. Regarding short-term risk, CATB is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs PRVB Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, CATB is priced at $8.54, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas PRVB's P/E ratio is -16.43. In terms of profitability, CATB's ROE is N/A, compared to PRVB's ROE of +1.33%. Regarding short-term risk, CATB is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs APLS Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, APLS has a market cap of 2.4B. Regarding current trading prices, CATB is priced at $8.54, while APLS trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas APLS's P/E ratio is -10.46. In terms of profitability, CATB's ROE is N/A, compared to APLS's ROE of -1.00%. Regarding short-term risk, CATB is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs LBPH Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, CATB is priced at $8.54, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas LBPH's P/E ratio is -26.66. In terms of profitability, CATB's ROE is N/A, compared to LBPH's ROE of -0.33%. Regarding short-term risk, CATB is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs DICE Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, CATB is priced at $8.54, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas DICE's P/E ratio is -21.91. In terms of profitability, CATB's ROE is N/A, compared to DICE's ROE of +0.56%. Regarding short-term risk, CATB is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs NAMS Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, NAMS has a market cap of 2.3B. Regarding current trading prices, CATB is priced at $8.54, while NAMS trades at $20.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -10.96. In terms of profitability, CATB's ROE is N/A, compared to NAMS's ROE of -0.33%. Regarding short-term risk, CATB is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for CATB.
CATB vs ARWR Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, CATB is priced at $8.54, while ARWR trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -12.69. In terms of profitability, CATB's ROE is N/A, compared to ARWR's ROE of -0.47%. Regarding short-term risk, CATB is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs LGND Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, CATB is priced at $8.54, while LGND trades at $112.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas LGND's P/E ratio is -15.43. In terms of profitability, CATB's ROE is N/A, compared to LGND's ROE of -0.16%. Regarding short-term risk, CATB is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs BCRX Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, BCRX has a market cap of 2.2B. Regarding current trading prices, CATB is priced at $8.54, while BCRX trades at $10.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas BCRX's P/E ratio is -39.85. In terms of profitability, CATB's ROE is N/A, compared to BCRX's ROE of +0.11%. Regarding short-term risk, CATB is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs VCEL Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, CATB is priced at $8.54, while VCEL trades at $42.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas VCEL's P/E ratio is 853.40. In terms of profitability, CATB's ROE is N/A, compared to VCEL's ROE of +0.01%. Regarding short-term risk, CATB is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CALT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, CATB is priced at $8.54, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CALT's P/E ratio is -22.73. In terms of profitability, CATB's ROE is N/A, compared to CALT's ROE of -1.67%. Regarding short-term risk, CATB is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs NAMSW Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, NAMSW has a market cap of 2.1B. Regarding current trading prices, CATB is priced at $8.54, while NAMSW trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CATB's ROE is N/A, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, CATB is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs DNLI Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, CATB is priced at $8.54, while DNLI trades at $14.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -5.56. In terms of profitability, CATB's ROE is N/A, compared to DNLI's ROE of -0.36%. Regarding short-term risk, CATB is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs VCYT Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, CATB is priced at $8.54, while VCYT trades at $26.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 62.95. In terms of profitability, CATB's ROE is N/A, compared to VCYT's ROE of +0.03%. Regarding short-term risk, CATB is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs KNSA Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, CATB is priced at $8.54, while KNSA trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is -117.92. In terms of profitability, CATB's ROE is N/A, compared to KNSA's ROE of -0.04%. Regarding short-term risk, CATB is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs AGIO Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, AGIO has a market cap of 2B. Regarding current trading prices, CATB is priced at $8.54, while AGIO trades at $34.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas AGIO's P/E ratio is 2.97. In terms of profitability, CATB's ROE is N/A, compared to AGIO's ROE of +0.50%. Regarding short-term risk, CATB is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.
CATB vs CGON Comparison
CATB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATB stands at 234.9M. In comparison, CGON has a market cap of 2B. Regarding current trading prices, CATB is priced at $8.54, while CGON trades at $25.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATB currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -17.24. In terms of profitability, CATB's ROE is N/A, compared to CGON's ROE of -0.17%. Regarding short-term risk, CATB is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CATB.